NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Omalizumab市場分析 (2021年∼2025年)

Investigation Report on China's Omalizumab Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1009409
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Omalizumab市場分析 (2021年∼2025年) Investigation Report on China's Omalizumab Market 2021-2025
出版日期: 2021年06月04日內容資訊: 英文 50 Pages
簡介

Omalizumab,是現在中國上市的唯一氣喘治療的單株抗體。2021前半年,Novartis Europharm是中國國內唯一的廠商。成中國的Omalizumab的銷售量有擴大趨勢,2018年∼2020年的年複合成長率成為163.2%,2020年的銷售額達4161萬人民幣 (與前一年同期比較增加281.5%) 。由於中國氣喘的死亡率在世界最高,市場今後也將繼續擴大趨勢。

本報告提供中國的Omalizumab的市場相關分析,產品的概要和授權情形,整體市場規模趨勢預測,各地區的詳細趨勢,市場價格趨勢預測,主要企業的簡介與市場佔有率,主要的推動及阻礙市場要素等資訊彙整,為您概述為以下內容。

目錄

第1章 Omalizumab的相關概念

  • Omalizumab的適應症
  • 中國國內的Omalizumab的開發趨勢
  • 中國政府的Omalizumab的核準情況
  • COVID-19對中國的Omalizumab銷售的影響

第2章 中國國內的Omalizumab銷售趨勢 (2018年∼2020年)

  • Omalizumab的銷售額
    • 總銷售額
    • 各地區的銷售額
  • Omalizumab的銷售量
    • 總銷售量
    • 各地區的銷售量
  • 中國國內的Omalizumab銷售趨勢:各劑型 (2018年∼2020年)
    • 注射劑
    • 其他劑型

第3章 中國的Omalizumab主要製造商分析 (2018年∼2020年)

  • 主要Omalizumab製造商市場佔有率分析
    • 市場佔有率:銷售額為基礎
    • 市場佔有率:銷售量為基礎
  • Novartis Europharm
    • 企業簡介
    • 中國的Omalizumab銷售趨勢

第4章 中國的Omalizumab的價格趨勢:各主要製造商 (2020年∼2021年)

  • Novartis Europharm (XOLAIR)
  • 其他企業分析

第5章 中國的Omalizumab市場未來展望 (2021年∼2025年)

  • 左右中國的Omalizumab市場趨勢的要素
    • COVID-19對中國的Omalizumab市場的影響
    • 市場促進因素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106508

Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA approved the registration of Novartis Europharm ' Omalizumab, which will enter the field of anti-COPD and moderate to severe persistent allergic asthma. Since then, Omalizumab has been officially launched in China. Omalizumab is the only monoclonal antibody currently on the market in China for the treatment of asthma. By the first half of 2021, Novartis Europharm is the only manufacturer in the Chinese Omalizumab market.

According to CRI's market research, Omalizumab sales have increased year by year from 2018 to 2020. At the beginning of 2020, Omalizumab was included in China's medical insurance as a treatment for respiratory diseases. During the period of the COVID-19 epidemic, the sales of Omalizumab has increased. Therefore, its sales value reached CNY41.61 million in China in 2020, with an annual growth rate of 281.5%. The CAGR of Omalizumab's sales value in the Chinese market from 2018 to 2020 is 163.2%.

CRI predicts that with the increase in the number of indications, the sales of Omalizumab in China will continue to grow from 2021 to 2025. China is one of the countries with the highest mortality rate of asthma in the world. In 2020, there were about 30 million asthma patients in China, which was 1.5 times higher than the number of patients in 2017 (20 million). Therefore, it can be speculated that the number of indications of Omalizumab in China will continue to grow and sales will increase accordingly. Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled B2-adrenergic receptor agonists, especially for patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future. In addition, Omalizumab has only been approved for one indication in China, and 4 indications have been approved globally. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase of the number of indications in the future.

Topics Covered:

  • The impact of COVID-19 on China's Omalizumab market
  • Sales value of China's Omalizumab 2016-2020
  • Competitive landscape of China's Omalizumab market
  • Prices of Omalizumab in China
  • Prices of Omalizumab in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Omalizumab market
  • Prospect of China's Omalizumab market from 2021 to 2025

Table of Contents

1 Relevant Concept of Omalizumab

  • 1.1 Indications for Omalizumab
  • 1.2 Development of Omalizumab in China
  • 1.3 Governmental Approval of Omalizumab in China
  • 1.4 The Impact of COVID-19 on Omalizumab sales in China

2 Sales of Omalizumab in China, 2018-2020

  • 2.1 Sales Value of Omalizumab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Omalizumab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Omalizumab by Dosage Form in China, 2018-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Omalizumab Manufacturers in China, 2018-2020

  • 3.1 Analysis of Market Share of Major Omalizumab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Novartis Europharm
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of XOLAIR (Novartis Europharm's Omalizumab) in China

4 Prices of Omalizumab for Different Manufacturers in China, 2020-2021

  • 4.1 Novartis Europharm (XOLAIR)
  • 4.2 Analysis of Other Enterprises

5 Prospect of Chinese Omalizumab drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Omalizumab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Omalizumab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Omalizumab Injection Registration in China
  • Chart Sales Value of Omalizumab Injection over the World
  • Chart Sales Value of Omalizumab Injection in China, 2018-2020
  • Chart Sales Value of Omalizumab Injection in China by Region, 2018-2020
  • Chart Sales Volume of Omalizumab Injection in China, 2018-2020
  • Chart Sales Volume of Omalizumab Injection in China by Region, 2018-2020
  • Chart Market Share by Sales Value of Top Omalizumab Manufacturers in China, 2018-2020
  • Chart Sales Value and Volume of XOLAIR in China, 2018-2020
  • Chart Referential Prices of XOLAIR in China, 2020-2021
  • Chart Forecast on Sales Value of Omalizumab in China, 2021-2025
  • Chart Forecast on Sales Volume of Omalizumab in China, 2021-2025